Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)

Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)

Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.

There is no more extensive information

Inclusion Criteria:

• patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosis-time less than four years.
• Over 18 years old. Forced vital capacity ≥ 40%.
• One year of evolution.
• Adequate nutritional state

Exclusion Criteria:

• Severe bulbar ALS involucre.
• Inadequate nutritional status.
• Spondylotic myelopathy, or abnormalities in imaging study.
• Having concomitant neurological or psychiatric disease.
• Systemic disease with poor-control.
• History of treatment with steroids or immunoglobulins in the last year.
• Participate in the past three months in a Clinical Trial.
• History of malignancy or cancer today.
• Intracranial hypertension.
• Clinical suggestive data of infection in the site of lumbar puncture.
• Tracheostomy.
• Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive or presence of antibodies against hepatitis B or C in the serological studies.